Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease-Reference-Cited by-同舟云学术

Novel Chemical Series of 5-Lipoxygenase-Activating Protein Inhibitors for Treatment of Coronary Artery Disease

Published:2019-03-30 Issue:9 Volume:62 Page:4325-4349
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Lemurell Malin^ORCID,Ulander Johan,Emtenäs Hans,Winiwarter Susanne^ORCID,Broddefalk Johan,Swanson Marianne,Hayes Martin A.^ORCID,Prieto Garcia Luna,Westin Eriksson Annika,Meuller Johan,Cassel Johan,Saarinen Gabrielle,Yuan Zhong-Qing,Löfberg Christian,Karlsson Staffan^ORCID,Sundqvist Monica,Whatling Carl

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.8b02012

Reference34 articles.

1. Leukotrienes

2. The potential link between atherosclerosis and the 5-lipoxygenase pathway: investigational agents with new implications for the cardiovascular field

3. What's all the FLAP about?: 5-lipoxygenase-activating protein inhibitors for inflammatory diseases

4. Pharmacodynamics, pharmacokinetics and safety of GSK2190915, a novel oral anti-inflammatory 5-lipoxygenase-activating protein inhibitor

5. Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Emerging Therapeutic Targets for Acute Coronary Syndromes: Novel Advancements and Future Directions;Biomedicines;2024-07-26

2. Structures of Leukotriene Biosynthetic Enzymes and Development of New Therapeutics;Annual Review of Pharmacology and Toxicology;2023-01-20

3. Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study;International Journal of Cardiology;2022-10

4. Pharmacokinetics, Pharmacodynamics, and Tolerability of AZD5718, an Oral 5-Lipoxygenase-Activating Protein (FLAP) Inhibitor, in Healthy Japanese Male Subjects;Clinical Drug Investigation;2021-09-21

5. Characterization and demonstration of drug compound ring-chain tautomer formation and its impacts on quality control;Journal of Pharmaceutical and Biomedical Analysis;2021-05